Clinical trial

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

NCT07428642

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2020-09-01

PhaseN/A

Study timeline

Study start (actual)2020-09-01Date precision: day

Registry last updated2026-03-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Hormone-Sensitive Prostate Cancerunresolved

Prostate Cancerunresolved

Interventions

Androgen Deprivation TherapyDRUG

ApalutamideDRUG · verified · RxNorm: apalutamide

EnzalutamideDRUG · verified · RxNorm: enzalutamide

DarolutamideDRUG · verified · RxNorm: darolutamide

RezvilutamideDRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

First Affiliated Hospital of Wenzhou Medical Universitylead sponsor

Second Affiliated Hospital of Wenzhou Medical Universitycollaborator

Ningbo No. 1 Hospitalcollaborator

Lishui Country People's Hospitalcollaborator

Sun Yat-Sen University Cancer Centercollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07428642 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.